Serial No: 09/670,756

REMARKS

-4-

Claims 1-54 were pending in the present application. Claims 1-7, 9 and 11-54 have been canceled without prejudice. Claims 8 and 10 have been amended and new claims 55-65 have been added. Accordingly, claims 8, 10 and 55-65 will be pending, after the amendments presented herein have been entered. For the Examiner's convenience all of the pending claims are set forth in Appendix A.

Attached hereto is a marked-up version of the changes made to claims by the current amendments. The attached page is captioned "Version With Markings to Show Changes Made".

Support for the newly added claims can be found throughout the specification including the originally filed claims. Specifically, support for new claims 55 and 65 can be found in claim 8 as originally filed. Support for new claims 56-58 can be found at page 10, lines 6-15 of the specification. Support for new claim 59 can be found at page 43, line 30 through page 44, line 4 of the specification. Support for new claims 60-62 can be found at page 55, lines 21-25 of the specification. Finally, support for claims 63 and 64 can be found in claim 9 as originally filed.

No new matter has been added. Any amendments to and/or cancellation of the claims should in no way be construed as an acquiescence to any of the Examiner's rejections and was done solely to expedite the prosecution of the application. Applicants reserve the right to pursue the claims as originally filed in this or a separate application(s).

RESPONSE TO RESTRICTION REQUIREMENT

Under 35 U.S.C. §121, the Examiner has required restriction to one of the Group I-Group LXXXIV inventions.

Applicants hereby elect the Group XIV invention (claims 8-10 drawn to isolated KChIP2 polypeptides comprising 81 Q ID XO = 10 000 Medical Applicants application, with transcript. Applicants respectfully request that the Examiner re-group and examine Groups XIV, XXVI, XXXVIII, LXII, LXXIV, on the grounds that they are connected in design, operation and effect, as required by MPI P8803. Moreover, as the M.P.L.P. states

Serial No: 09/670,756 -5- Group Art Unit: 1646

[i]f the search and examination of an entire application can be made without serious burden, the Examiner must examine it on the merits, even though it includes claims to independent of distinct inventions.

MPEP§803

The inventions of Groups XIV, XIV, XXVI, XXXVIII, LXII, and LXXIV all pertain to the KChIP2 polypeptide, antibodies thereto, and methods of use thereof. As such, the searches with regard to theses inventions would be co-extensive and would not involve a serious burden on the Examiner. Applicants therefore request that the examiner examines Groups XIV, XIV, XXVIII, LXII, and LXXIV.

Applicants reserve the right to traverse the restriction between the non-elected groups in this or a separate application.

CONCLUSION

In view of the amendments and remarks set forth above, it is respectfully submitted that this application is in condition for allowance. If there are any remaining issues or the Examiner believes that a telephone conversation with Applicants' Attorney would be helpful in expediting prosecution of this application, the Examiner is invited to call the undersigned at (617) 227-7400.

Respectfully submitted,

LAHIVE & COCKFIELD, LLP

Maria C. Laccotripe, Ph.D.

Limited Recognition Under 37 C.F.R. §10.9(b)

Attorney for Applicant

30 Sam Same

Boston, Massachusetts (22.08) retephone: (61.7.122 - 400) Facsimile: (617) 742-4214

Date: May 15, 2002

-6-

VERSION WITH MARKINGS TO SHOW CHANGES MADE

- 8. An isolated polypeptide selected from the group consisting of:
- a fragment of a polypeptide comprising the amino acid sequence of SEQ a) ID NO:2, SEO ID NO:4, SEO ID NO:6, SEO ID NO:8, SEO ID NO:10, SEO ID NO:12; SEO ID NO:14, SEO ID NO:16, SEO ID NO:18, SEO ID NO:20, SEO ID NO:22, SEO ID NO:24, SEO ID NO:26, SEO ID NO:28, SEO ID NO:30, SEO ID NO:32, SEO ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:49, SEQ ID NO:51, SEO ID NO:53, SEO ID NO:55, SEO ID NO:57, SEO ID NO:59, SEO ID NO:70, or SEO ID NO:72 or an amino acid sequence encoded by the DNA insert of the plasmid deposited with ATCC as Accession Number 98936, 98937, 98938, 98939, 98940, 98941, 98942, 98943, 98944, 98945, 98946, 98947, 98948, 98949, 98950, 98951, 98991, 98993, 98994, or PTA-316, wherein the fragment comprisesing at least 15 contiguous amino acids of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8. SEO ID NO:10, SEO ID NO:12, SEO ID NO:14, SEO ID NO:16, SEO ID NO:18, SEO ID NO:20, SEO ID NO:22, SEO ID NO:24, SEO ID NO:26, SEO ID NO:28, SEO ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEO ID NO:59, SEO ID NO:70, or SEO ID NO:72 or an amino acid sequence encoded by the DNA insert of the plasmid deposited with ATCC as Accession Number 98936, 98937, 98938, 98939, 98940, 98941, 98942, 98943, 98944, 98945, 98946, 98947, 98948, 98949, 98950, 98951, 98991, 98993, 98994, or PTA-316;
- b) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:55, SEQ ID NO:55, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:70, or SEQ ID NO:72 or an amino acid sequence encoded by the DNA insert of the plasmid deposited with A LCC as Accession Number

-7-

98936, 98937, 98938, 98939, 98940, 98941, 98942, 98943, 98944, 98945, 98946, 98947, 98948, 98949, 98950, 98951, 98991, 98993, 98994, or PTA-316, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:1, SEQ ID NO:3 SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:33, SEQ ID NO:25, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:56, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:56, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:69, or SEQ ID NO:71, or the DNA insert of the plasmid deposited with ATCC as Accession Number 98936, 98937, 98938, 98939, 98940, 98941, 98942, 98943, 98944, 98945, 98946, 98947, 98948, 98949, 98950, 98951, 98991, 98993, 98994, or PTA-316 under stringent conditions; and

- c) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 60% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3 SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:37, SEQ ID NO:50, SEQ ID NO:54, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:69, or SEQ ID NO:71, or the DNA insert of the plasmid deposited with ATCC as Accession Number 98936, 98937, 98938, 98939, 98940, 98941, 98942, 98943, 98944, 98945, 98946, 98947, 98948, 98949, 98950, 98951, 98991, 98993, 98994, or PTA-316.
- d)—a polypeptide comprising an amino acid sequence which is at least 60% identical to the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6. SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:30, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:35, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:70, or SEQ ID NO:72 or an amino acid sequence encoded by the DNA insert of the plasmid deposited with ATCC as

Serial No: 09/670,756 -8- Group Art Unit: 1646

Accession Number 98936, 98937, 98938, 98939, 98940, 98941, 98942, 98943, 98944, 98945, 98946, 98947, 98948, 98949, 98950, 98951, 98991, 98993, 98994, or PTA-316.

10. The polypeptide <u>of any one</u> of claims 8, <u>or 55-65</u> further comprising heterologous amino acid sequences.

Serial No: 09/670,756 -9- Group Art Unit: 1646

Appendix A

- 8. An isolated polypeptide comprising at least 15 contiguous amino acids of the amino acid sequence of SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, or SEQ ID NO:30.
- 10. The polypeptide of any one of claims 8, or 55-65 further comprising heterologous amino acid sequences.
- 55. An isolated naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, or SEQ ID NO:30.
- 56. An isolated a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 60% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, or SEQ ID NO:29.
- 57. An isolated a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 90% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:13, SFQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, or SEQ ID NO:29.
- 58. An isolated a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ

"Northic supplies and haddle of general challenger

many or selection of the selection of th

59. An isolated naturally occurring allelic variant of a protein consisting of the amino acid sequence of SLQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, or SEQ ID NO:30, wherein the protein

-10-

is encoded by a nucleic acid molecule which hybridizes to a complement of a nucleic acid molecule consisting of SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, or SEQ ID NO:29, respectively, in 6X SSC at 45° C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 50-65° C.

- 60. An isolated polypeptide comprising an amino acid sequence which is at least 60% identical to the amino acid sequence of SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, or SEQ ID NO:30.
- An isolated polypeptide comprising an amino acid sequence which is at least 90% identical to the amino acid sequence of SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, or SEQ ID NO:30.
- 62. An isolated polypeptide comprising an amino acid sequence which is at least 95% identical to the amino acid sequence of SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, or SEQ ID NO:30, wherein said polypeptide is capable of interacting with a potassium channel.
- 63. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, or SEQ ID NO:30.
- 64. An isolated polypeptide consisting of the amino acid sequence of SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, or SEQ ID NO:30.

ATCC as Accession Number 98937, 98939, 98941, 98947, 98948, 98950, 98951, 98991. or 98993.



BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE UNITED STATE PATENT AND TRADEMARK OFFICE

LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)

Maria C. Laccotripe is hereby given limited recognition under 37 CFR §10.9(b) as an employee of Lahive & Cockfield, LLP, to prepare and prosecute patent applications where the patent applicant is the client of Lahive & Cockfield, LLP, and the attorney or agent of record in the applications is a registered practitioner who is a member of the Lahive & Cockfield, LLP. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Maria C. Laccotripe ceases to lawfully reside in the United States, (ii) Maria C. Laccotripe's employment with Lahive & Cockfield, LLP ceases or is terminated, or (iii) Maria C. Laccotripe ceases to remain or reside in the United States on an H-1 visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: September 4, 2002

Harry L. Moatz

Director of Enrollment and Discipline